select a format

Single User License
USD 1500 INR 96240
Site License
USD 3000 INR 192480
Corporate User License
USD 4500 INR 288720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Boehringer Ingelheim GmbH-Product Pipeline Review-2015

Boehringer Ingelheim GmbH-Product Pipeline Review-2015


  • Products Id :- GMDHC07190CDB
  • |
  • Pages: 179
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Boehringer Ingelheim GmbH-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Boehringer Ingelheim GmbH-Product Pipeline Review-2015', provides an overview of the Boehringer Ingelheim GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boehringer Ingelheim GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Boehringer Ingelheim GmbH including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Boehringer Ingelheim GmbH's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Boehringer Ingelheim GmbH's pipeline products

Reasons To Buy

Evaluate Boehringer Ingelheim GmbH's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Boehringer Ingelheim GmbH in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Boehringer Ingelheim GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Boehringer Ingelheim GmbH and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Boehringer Ingelheim GmbH

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Boehringer Ingelheim GmbH and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Boehringer Ingelheim GmbH Snapshot 6

Boehringer Ingelheim GmbH Overview 6

Key Information 6

Key Facts 6

Boehringer Ingelheim GmbH-Research and Development Overview 7

Key Therapeutic Areas 7

Boehringer Ingelheim GmbH-Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products-Monotherapy 15

Pipeline Products-Combination Treatment Modalities 16

Pipeline Products-Partnered Products 17

Pipeline Products-Out-Licensed Products 19

Boehringer Ingelheim GmbH-Pipeline Products Glance 21

Boehringer Ingelheim GmbH-Late Stage Pipeline Products 21

Boehringer Ingelheim GmbH-Clinical Stage Pipeline Products 23

Boehringer Ingelheim GmbH-Early Stage Pipeline Products 26

Boehringer Ingelheim GmbH-Drug Profiles 29

(empagliflozin + metformin hydrochloride) 29

(olodaterol + tiotropium bromide) 31

idarucizumab 34

tiotropium bromide 35

adalimumab biosimilar 37

afatinib dimaleate 38

bevacizumab biosimilar 42

empagliflozin 43

nintedanib 45

rituximab biosimilar 49

volasertib 50

BI-144807 52

BI-409306 53

BI-655066 55

FX-125L 56

VTP-34072 58

BI-836845 60

BI-836858 62

BI-1005273 63

BI-1015550 64

BI-1026706 65

BI-1060469 66

BI-113608 67

BI-1361849 68

BI-416970 69

BI-425809 70

BI-655064 71

BI-836826 72

BI-847325 73

BI-853520 74

BI-860585 75

PXS-4728A 76

Small Molecule for Cancer 77

BCA-909 78

BI-1147560 80

BI-186908 81

BI-207524 Follow-Up 82

BIBN-4096BS 83

CNX-012 85

CNX-012570 86

Monoclonal Antibodies for Autoimmune Disorders 87

Monoclonal Antibodies for Oncology and Immunology 88

Small Molecule 2 for Cancer 89

Small Molecule 3 for Cancer 90

Small Molecule for Respiratory Diseases 91

Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain 92

Small Molecule to Agonize Glucocorticoid Receptor for Inflammation 93

Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 94

Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection 95

Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection 96

Small Molecules for Respiratory Disorders 97

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy 98

Synthetic Peptide for CardioMetabolic Disease 99

Synthetic Peptides to Agonize Glucagon and GLP-1 for Metabolic Disorders 100

Antibody for Cancer 101

BI-665915 102

Monoclonal Antibody for Undisclosed Indication 103

Small Molecule 2 to Agonize Glucocorticoid Receptor for Inflammation 104

Small Molecule for HIV 105

Small Molecule for HIV-1 Infection 106

Small Molecule to Agonize Glucocorticoid Receptor for Undisclosed Indication 107

Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders 108

Small Molecule to Inhibit Reverse Transcriptase for HIV-1 109

Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection 110

Small Molecules for Cancer 111

Small Molecules for Undisclosed Indication 112

Small Molecules to Inhibit K-Ras for Oncology 113

Small Molecules to Inhibit Kinases for Cancer 114

Boehringer Ingelheim GmbH-Pipeline Analysis 115

Boehringer Ingelheim GmbH-Pipeline Products by Target 115

Boehringer Ingelheim GmbH-Pipeline Products by Route of Administration 118

Boehringer Ingelheim GmbH-Pipeline Products by Molecule Type 119

Boehringer Ingelheim GmbH-Pipeline Products by Mechanism of Action 120

Boehringer Ingelheim GmbH-Recent Pipeline Updates 123

Boehringer Ingelheim GmbH-Dormant Projects 162

Boehringer Ingelheim GmbH-Discontinued Pipeline Products 165

Discontinued Pipeline Product Profiles 165

Boehringer Ingelheim GmbH-Company Statement 168

Boehringer Ingelheim GmbH-Locations And Subsidiaries 170

Head Office 170

Other Locations & Subsidiaries 170

Appendix 173

Methodology 173

Coverage 173

Secondary Research 173

Primary Research 173

Expert Panel Validation 173

Contact Us 173

Disclaimer 174

List of Tables

Boehringer Ingelheim GmbH, Key Information 11

Boehringer Ingelheim GmbH, Key Facts 11

Boehringer Ingelheim GmbH-Pipeline by Indication, 2015 13

Boehringer Ingelheim GmbH-Pipeline by Stage of Development, 2015 19

Boehringer Ingelheim GmbH-Monotherapy Products in Pipeline, 2015 20

Boehringer Ingelheim GmbH-Combination Treatment Modalities in Pipeline, 2015 21

Boehringer Ingelheim GmbH-Partnered Products in Pipeline, 2015 22

Boehringer Ingelheim GmbH-Partnered Products/ Combination Treatment Modalities, 2015 23

Boehringer Ingelheim GmbH-Out-Licensed Products in Pipeline, 2015 24

Boehringer Ingelheim GmbH-Out-Licensed Products/ Combination Treatment Modalities, 2015 25

Boehringer Ingelheim GmbH-Pre-Registration, 2015 26

Boehringer Ingelheim GmbH-Phase III, 2015 27

Boehringer Ingelheim GmbH-Phase II, 2015 28

Boehringer Ingelheim GmbH-Phase I, 2015 29

Boehringer Ingelheim GmbH-Preclinical, 2015 31

Boehringer Ingelheim GmbH-Discovery, 2015 33

Boehringer Ingelheim GmbH-Pipeline by Target, 2015 120

Boehringer Ingelheim GmbH-Pipeline by Route of Administration, 2015 123

Boehringer Ingelheim GmbH-Pipeline by Molecule Type, 2015 124

Boehringer Ingelheim GmbH-Pipeline Products by Mechanism of Action, 2015 125

Boehringer Ingelheim GmbH-Recent Pipeline Updates, 2015 128

Boehringer Ingelheim GmbH-Dormant Developmental Projects,2015 167

Boehringer Ingelheim GmbH-Discontinued Pipeline Products, 2015 170

Boehringer Ingelheim GmbH, Subsidiaries 175

List of Figures

Boehringer Ingelheim GmbH-Pipeline by Top 10 Indication, 2015 13

Boehringer Ingelheim GmbH-Pipeline by Stage of Development, 2015 19

Boehringer Ingelheim GmbH-Monotherapy Products in Pipeline, 2015 20

Boehringer Ingelheim GmbH-Combination Treatment Modalities in Pipeline, 2015 21

Boehringer Ingelheim GmbH-Partnered Products in Pipeline, 2015 22

Boehringer Ingelheim GmbH-Out-Licensed Products in Pipeline, 2015 24

Boehringer Ingelheim GmbH-Pipeline by Top 10 Target, 2015 120

Boehringer Ingelheim GmbH-Pipeline by Top 10 Route of Administration, 2015 123

Boehringer Ingelheim GmbH-Pipeline by Top 10 Molecule Type, 2015 124

Boehringer Ingelheim GmbH-Pipeline Products by Top 10 Mechanism of Action, 2015 125

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Boehringer Ingelheim GmbH; Boehringer Ingelheim GmbH - Key Therapeutics; Boehringer Ingelheim GmbH - Pipeline Overview and Promising Molecules; Boehringer Ingelheim GmbH - News; Boehringer Ingelheim GmbH - Latest Updates; Boehringer Ingelheim GmbH - Pipeline; Boehringer Ingelheim GmbH - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com